A review of famciclovir in the management of genital herpes

Infectious Diseases in Obstetrics and Gynecology

Volumn 6, Issue 1, 1998, Pages 38-43

  Faro, S ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiviral therapy; Genital herpes; Herpes simplex infection; Recurrent genital herpes

Indexed keywords

ACICLOVIR; FAMCICLOVIR; PENCICLOVIR; PLACEBO; VALACICLOVIR;

CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GENITAL HERPES; HEADACHE; HERPES SIMPLEX VIRUS; HUMAN; LIFE CYCLE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

2-AMINOPURINE; ANTIVIRAL AGENTS; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS;

EID: 0031864804     PISSN: 10647449     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-0997(1998)6:1<38::AID-IDOG8>3.0.CO;2-3     Document Type: Review

References (35)

1. Catotti DN, Clarke P, Catoe KE: Herpes revisited: still a cause of concern. Sex Transm Dis 20:77-80, 1993.
2. Fleming DT, McQuillan GM, Johnson RE, et al.: Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 337:1105-1111, 1997.
3. Lavery HA, Connolly JH, Russell JD: Incidence of herpes genitalis in Northern Ireland in 1973-1983 and herpes simplex types 1 and 2 isolated in 1982-4. Genitourin Med 62:24-27, 1986.
4. Straus SE, Rooney JF, Sever JL, et al.: Herpes simplex virus infection: biology, treatment, and prevention. Ann Intern Med 103:404-419, 1985.
5. Corey L, Spear PG: Infections with herpes simplex viruses. N Engl J Med 314:686-691, 1986.
6. Landy HJ, Grossman JH: Herpes simplex virus. Sex Transm Dis 16:495-515, 1989.
7. Sacks SL: Genital herpes simplex virus infection and treatment. In: Sacks SL, Straus SE, Whitley RJ, Griffiths PD (eds): Clinical Management of Herpes Viruses. Amsterdam: IOS Press, pp 55-74, 1995.
8. Benedetti J, Corey L, Ashley R: Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 121:847-854, 1994.
9. Corey L, Adams HG, Brown ZA, Holmes KK: Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 98:958-972, 1983.
10. Whitley RJ, Gnann JW: Acyclovir: a decade later. N Engl J Med 327:782-789, 1992.
11. Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, Perkins RM, Vere Hodge RA: Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2 and varicella-zoster virus. Antimicrob Agents Chemother 36:2747-2757, 1992.
12. Weller S, Blum MR, Doucette M, et al.: Pharmacokinetics of the acyclovir pro-drug valacyclovir after escalating single and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 54:595-605, 1993.
13. Tyring SK, Barbarash RA, Nahlik MD, et al.: Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A 1986 randomized, double-blind, placebo-controlled trial. Ann Intern Med 123:89-96, 1995.
14. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, and Shafran S for the Canadian Cooperative Study Group: Patient-initiated, twice-daily oral famciclovir for early re current genital herpes: a randomized, double-blind multicenter trial. JAMA 276:44-49, 1996.
15. Vere Hodge RA, Sutton D, Boyd M, Harnden MR, Jarvest RL: Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; penciclovir]. Antimicrob Agents Chemother 33:1765-1773, 1989.
16. Vere Hodge RA: Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem Chemother 4:67-84, 1993.
17. 13C NMR to identify the chiral monoacylated intermediates in the conversion of famciclovir to penciclovir by human intestinal wall extract. Chirality 5:577-582, 1993.
18. Vere Hodge RA, Perkins RM: Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother 33:223-229, 1989.
19. Boyd MR, Bacon TH, Sutton D, Cole M: Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother 31:1238-1242, 1987.
20. Vere Hodge RA, Cheng Y-C: The mode of action of penciclovir. Antiviral Chem Chemother 4(suppl 1):13-24, 1993.
21. Pue MA, Benet LZ: Pharmacokinetics of famciclovir in man. Antiviral Chem Chemother 4(suppl 1):47-55, 1993.
22. Fowles SE, Pierce DM, Prince WT, Thow JC: Effect of food on the bioavailability and pharmacokinetics of penciclovir, a novel antiherpes agent, following oral administration of the pro-drug famciclovir. Br J Clin Pharmacol 29:620P-621P, 1990 (abstract).
23. Fowles SE, Fairless AJ, Pierce DM, Prince WJ: A further study of the effect of food on the bioavailability and pharmacokinetics of penciclovir after oral administration of famciclovir. Br J Clin Pharmacol 32:657P, 1991 (abstract).
24. Daniels S, Schentag JJ: Drug interaction studies and safety of famciclovir in healthy volunteers: a review. Antiviral Chem Chemother 4(suppl 1):57-64, 1993.
25. Rousseau F, Scott S, Pratt S, et al.: Safe coadministration of famciclovir and zidovudine. In: Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 4-7, 1994; Orlando, FL. Abstract A64.
26. Saltzman R, Jurewicz R, Boon R: Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother 38:2454-2457, 1994.
27. Boon R, Saltzman R, Atkinson GF: The clinical safety experience with famciclovir. Hepatol 24:282A, 1996.
28. Sacks SL, Martel A, Aoki F et al.: Clinic-initiated treatment of recurrent genital herpes using famciclovir: results of a Canadian multicenter study. Presented at the 6th International Congress for Infectious Diseases; 1994; Prague, Czech Republic.
29. Mertz G, Loveless MO, Levin MJ, et al.: Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. Arch Intern Med 157:343-349, 1997.
30. Mindel G, Faherty A, Carney O, et al.: Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet 8591:926-928, 1997.
31. Tyring SK and the International Valaciclovir HSV Study Group. Once-daily valaciclovir for suppression of genital herpes-Results from a large, international, controlled study. Presented at the American Academy of Dermatology, San Francisco, CA. 21-26, March 1997.
32. Loveless M, Harris W, Sacks S: Treatment of first episode genital herpes with famciclovir. In: Abstracts of the 35th Interscience Conference of Antimicrobial Agents in Chemotherapy; September 17-20, 1995; San Francisco, CA. Abstract H12.
33. Field HJ, Thackray AM: The effects of delayed-onset chemotherapy using famciclovir or valaciclovir in a murine immunosuppression model for HSV-1. Antiviral Chem Chemother 6:210-216, 1995.
34. Thackray AM, Field HJ: Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in murine infection model including reactivation from latency. J Infect Dis 173:291-299, 1996.
35. Ahmed A, Woolley PD: Comparison of famciclovir and acyclovir in first episodes of genital herpes: possible effect on latency. European Conference on Herpesviruses; 1996; Paris, France.